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Metastasis is strongly inhibited in thrombocytopenic mice. This phenotype is reversed by NK cell depletion which
indicates that platelets may facilitate tumor progression and metastasis by interfering with NK cell immunosurveillance.
Understanding the underlying mechanisms may help us to reinforce anti-tumor immunity and NK-based immunotherapy
in cancer patients.
NK cells are cytotoxic lymphocytes, which
play a major role in anti-tumor immunity
and can prevent tumor progression and
metastasis. Their reactivity is guided by the
principles of “missing self” and “induced
self” recognition, which imply that cells
with low or absent expression of MHC
class I (“missing self”) and/or expression of
stress-induced ligands for activating NK
receptors (“induced self”) are preferentially
recognized and eliminated by NK cells. In
addition, reciprocal interactions of NK
cells with other hematopoietic cells such
as dendritic cells have been described to
result in altered reactivity of both involved
cell types.
1 The interplay of NK cells with
platelets was by far less studied, although
the latter have been known for many years
to facilitate tumor progression and meta-
stasis. Platelets may influence tumor cells
through multiple mechanisms including
release of growth factors that stimulate
tumor proliferation and neoangiogenesis
or by facilitating vessel wall penetration
thereby opening metastasizing cells in
the blood the door to their metastatic
niche.
2 More recently, their immuno-
modulatory properties are increasingly
being recognized.
3 In mice, there is little
to no metastasis in the absence of platelets,
and this is reversed by additional depletion
of NK cells.
4 Thus, inhibition of NK
reactivity may be crucial for the metastasis-
promoting effects of platelets. However,
besides mechanistic hypotheses proposing
that tumor cells may “hide behind”
platelets thereby preventing access of
immune cells, the molecular mechanisms
influencing platelet-tumor-NK cell inter-
action were largely unclear.
2
In our recent work
5 we unravel transfer
of MHC class I to malignant cells by
platelets as a mechanism whereby (meta-
stasizing) tumor cells “hide” from “missing
self” recognition by NK cells. Various flow
cytometric and microscopic techniques
including confocal and immuno-electron
microscopy revealed that constitutively
MHC Class I-negative/low tumor cells
acquire MHC Class I upon interaction
with platelets. Analyses with allotype-
specific antibodies confirmed that MHC
class I was in fact transferred to the tumor
cells and excluded that platelets merely
induced upregulation of the tumor cells’
own MHC. NK reactivity was impaired in
cultures with tumor cells that displayed
MHC Class I derived from platelets of
the NK cell donor. Blocking MHC Class
I restored NK reactivity under this con-
dition, while responses to tumor cells that
had not been exposed to platelets were
not altered.
Our findings indicate how (metastasiz-
ing) tumor cells may downregulate MHC
Class I to evade T-cell anti-tumor reac-
tivity
6 without becoming prone to NK
immunosurveillance due to an immuno-
phenotype of false pretenses: the transfer
of platelet-derived MHC Class I mole-
cules that present “unsuspicious” peptides
reflecting the normal ligandome of the
megakaryocyte lineage would not stimu-
late T-cell responses but result in an
NK-inhibitory “pseudo-self” phenotype.
It should be noted that beyond prevention
of “missing self” detection by platelet-
derived MHC Class I, multiple other
immunomodulatory ligands for receptors
expressed on NK cells can be transferred
by platelets and certainly also influence
NK anti-tumor immunity.
7 The picture
becomes even more complex when we
consider that platelets may also influence
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the reactivity of NK cells by soluble factors
that are released upon tumor cell-platelet
interaction. This comprises secretion of
TGFβ, which causes downregulation of
NKG2D on NK cells. NKG2D plays a
prototypical role in NK “induced self”
recognition, and reduction of its expression
by platelet releasate results in impaired
reactivity against NKG2Dligand-expressing
tumor targets.
8 Again, multiple other
platelet-derived cytokines and growth
factors certainly also play a role.
3,7
Together, current data indicate that
platelets influence NK cells by multiple
different mechanisms. This may also
explain discrepancies between our results
and e.g., the findings of Nieswandt et al.
in the murine system, who found that
platelets impaired NK cytotoxicity by
a mechanism independent from MHC
Class I in their experimental setting.
4 In
line with the concept that NK cell
responses are governed by a balance of
signals mediated by multiple activating
and inhibitory receptors,
1 the available
data show that platelets influence NK cell
anti-tumor reactivity by various mechan-
isms including impaired “induced self”
and “missing self” recognition with multi-
ple soluble and membrane-bound mole-
cules being involved. Since platelets also
affect immune effector cells other than
NK cells, promote metastasis by multiple
mechanisms beyond influencing anti-
tumor immunity, and because metastatic
tumor spread is also influenced by the
plasmatic coagulation system,
7 dissec-
tion of specific tumor-promoting effects
mediated by platelets is challenging. This
especially holds true for animal models,
where species-specific differences between
mice and men with regard to the function
of immunomodulatory molecules (includ-
ing those expressed by platelets) may
additionally come into play.
2,7 Thus, while
mouse models have largely added to our
understanding of the role of platelets in
immunity in the past and will certainly
Figure1. The role of platelet-derived “pseudo-self” in tumor immune evasion. (A) T cell immunity is mediated by recognition of tumor antigens
presented by the tumor cell’s own MHC Class I; the latter at the same time inhibits NK cell reactivity. (B) MHC Class I downregulation enables escape from
T cell immunity but renders tumor cells susceptible to NK “missing self” recognition. (C) Transfer of platelet MHC Class I results in a “pseudo-self”
phenotype which impairs NK immunosurveillance by concealing the “missing self” without inducing T cell reactivity due to presentation of
“unsuspicious” peptides.
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do so in the future, the understanding of
NK-evasion mechanisms mediated by
platelets is well aided by rational in vitro
and ex vivo analyses. Our recent publica-
tion may serve well to exemplify such
approaches.
The trilateral crosstalk of NK cells,
platelets, and tumor cells in cancer pro-
gression and metastasis obviously consti-
tutes a complex mechanism, which we
presently are only beginning to understand.
Notably, data from mouse models util-
izing inhibitors of platelet aggregation
indicate that adhesion (potentially resulting
in transfer of immunoregulatory molecules)
may be more relevant than aggregation
(associated with release of soluble factors)
for enabling tumor cell dissemination.
9
This underlines the relevance of the trans-
fer of immunoregulatory molecules between
platelets and tumor cells as described in our
study,
5 but also has important implications
for pharmacological approaches aiming
to prevent metastasis-enhancing platelet
effects.
2,7 As numerous attempts are
presently being made to introduce NK
cells in the treatment of cancer,
10 we are
convinced that a better understanding of
how platelets contribute to the evasion of
tumor cells from NK anti-tumor react-
ivity holds promise to identify strategies
that ultimately may improve immuno-
therapeutic options for cancer patients.
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